UNSPSC 51111828: Cyproterone

This classification denotes an anti-androgen with the molecular formula C22H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E61Q31EK2F, chemically known as 3h-cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 6-chloro-1-beta,2-beta-dihydro-17-hydroxy- but generally known as cyproterone, which bears US NIH Compound Identifier 16417. European Medicines Agency schedules Cyproterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06877MIG.

UNSPSC 51111828 Cyproterone, a Commodity code, encompasses generic pharmaceutical products and over-the-counter medications that state and local health systems, correctional facilities, and social service agencies procure through cooperative purchasing vehicles and direct contracts. The work involves supplying finished pharmaceutical products with verified National Drug Codes, SKUs, and UPCs; meeting current Good Manufacturing Practices and Drug Supply Chain Security Act compliance; maintaining relationships with authorized wholesalers; and managing pricing through formats including flat price, net price tiers, or WAC-minus structures. Issuing bodies include state purchasing offices administering multistate cooperative agreements, county health departments, correctional systems, and local government facilities; these entities typically source through cooperative vehicles rather than individual jurisdictional procurements to leverage volume and standardize supply chains across multiple states and agencies.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued a Request for Proposal on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The MMCAP solicitation spans participating state and local facilities across Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—with contracts effective July 1, 2026. Evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, EDI capability and administrative fee compliance at 5 percent each, and administrative data format compliance at 5 percent. Vendors must carry commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and products must maintain at least six months shelf life with expiration dates one year from manufacture.